Pascale Augé
Directeur Général chez Inserm-Transfert SA
Profil
Pascale Augé is currently the Chairman-Management Board at Inserm-Transfert SA, Director at Laboratoire Français du Fractionnement et des Biotechnologies, Director at INSERM Transfert Initiative SAS, Director at Linkinvax SA, and Independent Director at eureKING SA. In the past, Dr. Augé worked as a Senior Manager at Ernst & Young Audit SAS (France) from 2004 to 2011, as a Project Manager at AB Science SA from 2003 to 2004, and as a Project Manager at Novachim SA.
Postes actifs de Pascale Augé
| Sociétés | Poste | Début |
|---|---|---|
Laboratoire Français du Fractionnement et des Biotechnologies
 Laboratoire Français du Fractionnement et des Biotechnologies BiotechnologyHealth Technology Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France. | Directeur/Membre du Conseil | - |
Inserm-Transfert SA
 Inserm-Transfert SA Miscellaneous Commercial ServicesCommercial Services Inserm-Transfert SA engages in the managements of economic and societal value creation and the transfer of knowledge. It operates in the human health innovation sector. The company was founded in 2000 and is headquartered in Paris, France. | Directeur Général | 01/01/2014 |
Linkinvax SA
 Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Linkinvax SA is a French company founded in 2020 by Remi Gaston-Dreyfus, Yves Lévy, André-Jacques Auberton-Hervé, Laurent Hanot, and Mireille Centlivre. The company is based in Paris, France. Linkinvax is developing an innovative protein-based vaccine platform that can accelerate the availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). The platform is DC targeting-based and can adapt to changes and mutations in the target pathogens. Linkinvax aims to revolutionize vaccine development, particularly for new viruses like Chlamydia and COVID-19. The company is led by André-Jacques Auberton-Hervé, who has been the CEO since 2020. | Directeur/Membre du Conseil | - |
eureKING SA
 eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | Directeur/Membre du Conseil | 05/05/2022 |
INSERM Transfert Initiative SAS
 INSERM Transfert Initiative SAS Investment ManagersFinance INSERM Transfert Initiative SAS is a venture capital fund that invests in companies located in France. It targets startups from the life sciences and biotechnology sectors, developing new medical practices with a strong intellectual property. It invests between €1 million and €3 million per company during mostly at pre-seed, seed and early-stages. | Directeur/Membre du Conseil | - |
Anciens postes connus de Pascale Augé
| Sociétés | Poste | Fin |
|---|---|---|
Ernst & Young Audit SAS (France)
 Ernst & Young Audit SAS (France) Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Ernst & Young Audit SAS (France) is a French company that provides auditing and accounting services. The company is based in Courbevoie, France. Founded in 1987. | Corporate Officer/Principal | 01/01/2011 |
| AB SCIENCE | Corporate Officer/Principal | 01/01/2004 |
| Novachim SA | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AB SCIENCE | Health Technology |
| Entreprise privées | 7 |
|---|---|
Laboratoire Français du Fractionnement et des Biotechnologies
Laboratoire Français du Fractionnement et des Biotechnologies BiotechnologyHealth Technology Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France. | Health Technology |
Inserm-Transfert SA
Inserm-Transfert SA Miscellaneous Commercial ServicesCommercial Services Inserm-Transfert SA engages in the managements of economic and societal value creation and the transfer of knowledge. It operates in the human health innovation sector. The company was founded in 2000 and is headquartered in Paris, France. | Commercial Services |
Linkinvax SA
Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Linkinvax SA is a French company founded in 2020 by Remi Gaston-Dreyfus, Yves Lévy, André-Jacques Auberton-Hervé, Laurent Hanot, and Mireille Centlivre. The company is based in Paris, France. Linkinvax is developing an innovative protein-based vaccine platform that can accelerate the availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). The platform is DC targeting-based and can adapt to changes and mutations in the target pathogens. Linkinvax aims to revolutionize vaccine development, particularly for new viruses like Chlamydia and COVID-19. The company is led by André-Jacques Auberton-Hervé, who has been the CEO since 2020. | Commercial Services |
eureKING SA
eureKING SA Financial ConglomeratesFinance eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France. | Finance |
INSERM Transfert Initiative SAS
INSERM Transfert Initiative SAS Investment ManagersFinance INSERM Transfert Initiative SAS is a venture capital fund that invests in companies located in France. It targets startups from the life sciences and biotechnology sectors, developing new medical practices with a strong intellectual property. It invests between €1 million and €3 million per company during mostly at pre-seed, seed and early-stages. | Finance |
| Novachim SA | |
Ernst & Young Audit SAS (France)
Ernst & Young Audit SAS (France) Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Ernst & Young Audit SAS (France) is a French company that provides auditing and accounting services. The company is based in Courbevoie, France. Founded in 1987. | Commercial Services |
